“Biopta has provided Proteon with high quality data in human tissue to guide dose selection for human clinical trials.  The information has been extremely valuable in demonstrating the potential benefit of PRT-201 in patients needing hemodialysis access or treatment of peripheral arterial disease.  The information has and will continue to be an important part of our nonclinical data for regulatory submissions”.
Senior Vice President and Chief Medical Officer, Proteon Therapeutics Inc.

 Download the case study to see how Biopta helped accelerate Proteon's development programme.

“We were attracted to Biopta because they are able to provide sensitive and accurate information from a wide range of different types of tissue, which similar companies cannot do. They can also combine standard screening with valuable information on mechanism, I was impressed with that”.
CEO, UK Biotech

“Biopta's human tissue services have played a critical part in our compound selection and have added considerable value to our lead compound. At our last round of funding, the investors were reassured by the presence of functional data on living human tissues”.
President & Head of R&D, Canadian Biotech

“I am very pleased with our cooperation so far; nice data and very good fit to our internal knowledge of the compounds”.
Senior Scientist, Top 20 European Pharma

Live chat by BoldChat